Molecularly guided therapy in gastrointestinal malignancies: From established targets to resistance and emerging precision strategies
World Journal of Translational Medicine · 28.11.2026 · 12 (4)
DOI: 10.5528/wjtm.127329 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Translational Medicine, online erschienen am 28.11.2026. Verfasst von Himanshu Agrawal und 2 weiteren Autor:innen. Die Arbeit nennt 135 Literaturangaben.
Abstract (Originalsprache)
Gastrointestinal (GI) malignancies comprise a heterogeneous group of cancers in which molecular alterations increasingly guide therapeutic selection. Biomarker-driven therapies are established in selected colorectal, gastric and gastroesophageal junction, biliary, pancreatic, and GI stromal tumors. However, primary and acquired resistance, tumor heterogeneity, evolving molecular profiles, and unequal access to molecular diagnostics limit durable benefit. This narrative review evaluates the current landscape of molecularly targeted therapies across major GI malignancies, focusing on validated molecular targets, clinical evidence, biomarker selection, resistance mechanisms, and emerging therapeutic strategies. A structured literature search was conducted in PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar for publications from January 2000 to 30 July 2026. Evidence was narratively synthesized according to tumor type and molecular target and graded as A (randomized phase III evidence or established standard of care), B (prospective phase II or substantial clinical evidence), C (early-phase, retrospective, or limited clinical evidence), or D (preclinical or experimental evidence). Molecularly targeted therapy is now an established component of treatment for selected molecular subgroups. Key advances include genotype-directed therapy in colorectal cancer and cholangiocarcinoma, human epidermal growth factor receptor 2- and claudin 18.2-directed approaches in gastric cancer, KIT proto-oncogene receptor tyrosine kinase/platelet-derived growth factor receptor alpha-directed treatment in GI stromal tumor, and molecularly selected strategies in pancreatic cancer. Resistance, intratumoral heterogeneity, molecular evolution, and inconsistent biomarker assessment remain major barriers. Emerging approaches include next-generation inhibitors, antibody–drug conjugates, bispecific antibodies, cellular therapies, circulating tumor DNA-guided treatment, targeted–immunotherapy combinations, and tissue-agnostic strategies. Further progress will require accessible biomarker testing, longitudinal molecular assessment, rational treatment sequencing, and prospective evaluation of emerging precision therapies.
Zitieren
APA
Agrawal, H., Goel, S., & Gupta, N. (2026). Molecularly guided therapy in gastrointestinal malignancies: From established targets to resistance and emerging precision strategies. World Journal of Translational Medicine, 12(4). https://doi.org/10.5528/wjtm.127329
Vancouver
Agrawal H, Goel S, Gupta N. Molecularly guided therapy in gastrointestinal malignancies: From established targets to resistance and emerging precision strategies. World Journal of Translational Medicine. 2026;12(4). doi:10.5528/wjtm.127329
BibTeX
@article{Agrawal2026,
author = {Agrawal, Himanshu and Goel, Sahil and Gupta, Nikhil},
title = {Molecularly guided therapy in gastrointestinal malignancies: From established targets to resistance and emerging precision strategies},
journal = {World Journal of Translational Medicine},
year = {2026},
volume = {12},
number = {4},
doi = {10.5528/wjtm.127329}
}
EUVIMED